Kyverna Q3 net loss $34.3M; CMO James Chung resigns effective Nov 22

Kyverna Therapeutics, Inc.

2024-Q3 EPS reported -$2.45

Net loss of $34.3M ($0.80 per share) vs. $15.5M loss in prior-year quarter.
Cash, equivalents and marketable securities $321.6M as of Sep 30, 2024.
CMO James Chung, M.D., Ph.D. resigns effective Nov 22; search for replacement underway.
CEO Warner Biddle appointed; Board adds Christi Shaw and Mert Aktar.
KYV-101 advances: Phase 2 dosing in myasthenia gravis; RMAT and Orphan Drug designations in multiple indications.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James Chung

Chief Medical Officer

KYTX · Kyverna Therapeutics, Inc.

Effective: 2024-11-22
Filed: November 13, 2024, 6:59 PM ET

On November 8, 2024, James Chung, M.D., Ph.D., Chief Medical Officer of the Company, resigned from the Company, to be effective as of November 22, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James Chung resigned as Chief Medical Officer at Kyverna Therapeutics, Inc..

Action: resigned
Role: Chief Medical Officer

Exact text from the filing

On November 8, 2024, James Chung, M.D., Ph.D., Chief Medical Officer of the Company, resigned from the Company, to be effective as of November 22, 2024.

View on SEC.gov

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-126342

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.